PT - JOURNAL ARTICLE AU - Dupnik, Kathryn AU - Rivera, Vanessa R. AU - Dorvil, Nancy AU - Akbarnejad, Hanane AU - Gao, Yipeng AU - Liu, Jingyi AU - Apollon, Alexandra AU - Dumond, Emelyne AU - Riviere, Cynthia AU - Severe, Patrice AU - Lavoile, Kerlyne AU - Duran Mendicuti, Maria Alejandra AU - Pierre, Samuel AU - Rouzier, Vanessa AU - Walsh, Kathleen F. AU - Byrne, Anthony L. AU - Joseph, Patrice AU - Cremieux, Pierre-Yves AU - Pape, Jean William AU - Koenig, Serena P. TI - Potential Utility of C-reactive Protein for Tuberculosis Risk Stratification among Patients with Non-Meningitic Symptoms at HIV Diagnosis in Low- and Middle-Income Countries AID - 10.1101/2023.12.19.23300232 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.19.23300232 4099 - http://medrxiv.org/content/early/2023/12/20/2023.12.19.23300232.short 4100 - http://medrxiv.org/content/early/2023/12/20/2023.12.19.23300232.full AB - Article Summary We assessed the association between C-reactive protein (CRP) and Mycobacterium tuberculosis (TB) diagnosis in symptomatic patients at HIV diagnosis. We found that CRP concentrations can improve tuberculosis risk stratification, facilitating decision making about whether (specific) tuberculosis testing is indicated before antiretroviral therapy initiation.Background The World Health Organization recommends initiating same-day ART while tuberculosis testing is underway for patients with non-meningitic symptoms at HIV diagnosis, though safety data are limited. C-reactive protein (CRP) testing may improve tuberculosis risk stratification in this population.Methods In this baseline analysis of 498 adults (>18 years) with tuberculosis symptoms at HIV diagnosis who were enrolled in a trial of rapid ART initiation in Haiti, we describe test characteristics of varying CRP thresholds in the diagnosis of TB. We also assessed predictors of high CRP (≥3 mg/dL) using generalized linear models.Results Eighty-seven (17.5%) patients were diagnosed with baseline TB. The median CRP was 33.0 mg/L (IQR: 5.1, 85.5) in those with TB, and 2.6 mg/L (IQR: 0.8, 11.7) in those without TB. As the CRP threshold increased from ≥1 mg/L to ≥10 mg/L, the positive predictive value for TB increased from 22.4% to 35.4%, and negative predictive value decreased from 96.9% to 92.3%. With CRP thresholds varying from <1 to <10 mg/L, a range from 25.5% to 64.9% of the cohort would have been eligible for same-day ART, and 0.8% to 5.0% would have untreated TB at ART initiation.Conclusions CRP concentrations can be used to improve TB risk stratification, facilitating same-day decisions about ART initiation. Depending on the CRP threshold, one-quarter to two-thirds of patients could be eligible for same-day ART, with a reduction of 3-fold to 20-fold in the proportion with untreated TB, compared with a strategy of same-day ART while awaiting TB test results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a grant from the National Institute of Allergy and Infectious Diseases (R01AI131998; primary investigator: SK). KD was supported by NIAID (K23AI131913) and a Doris Duke Charitable Foundation Clinical Scientist Development Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review boards at GHESKIO, Mass General Brigham, and Weill Cornell Medical College. Written informed consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors